← Eichor
Condition: Peripheral T Cell Lymphomas Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Peripheral T Cell Lymphomas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04045470A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931263Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07293403MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular H
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05572983Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048Go-CHOP as the Frontline Therapy for PTCL
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05963347Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07372352Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Pr
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05958719Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106Genotype-guided Treatment in Newly Diagnosed PTCL
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT05675813GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06244368A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06914037Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Perip
Phase 3 · 1 location(s) · Evopoint Biosciences Inc. · NCT06776952A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of New
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06630091Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a Ne
Phase 1/Phase 2 · 8 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06378190An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal A
EARLY_Phase 1 · 1 location(s) · Second Affiliated Hospital of Soochow University · NCT07598578Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05949944Linperlisib Combined With Chidamide in Patients With PTCL
Phase 1/Phase 2 · 6 location(s) · Yanyan Liu · NCT06421948CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Phase 2 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04083495Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074457Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.